Genmab — Februar 2026
-
Importantly, we see increasing adoption in naive patients, which are now 50% of our NBRx is now in first line. Outside of the U.S., we are leading now with NBRx share in 9 out of the 10 of the major markets that we track. And the core opportunity we see ex U.S. going forward is to continue to expand B-cell therapies in the 67% of patients who are not on B-cell therapies and receiving disease-modifying therapies in MS.
-
Skulle regnskab ikke komme idag kl 17 ? Kommer det efter kl 22?
-
How Does Rina-S Work in Patients With Pretreated Endometrial Cancer? https://www.oncnursingnews.com/view/how-does-rina-s-work-in-patients-with-pretreated-endometrial-cancer-
-
Selvfølgelig , hvis de afventer en godkendelse på noget der kan rykke deres fremtidige indtjening væsentligt positivt eller negativt, så kan jeg forstå at de udskyder det, men ellers ikke. Glæder mig til at se regnskabet.
-
Godmorgen
-
Forhåbentlig følger kursen ikke temperaturen lige p.t.
-
Men skal vi lige teste støtten igen monstro?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind